Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 16.52 as of 2026-10-06T19:17:58.578Z.
Consensus retrieved: 2026-10-06T14:50:18.475Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:17:58.578Z.
Quote observation: 2026-10-06T19:15:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4d295692773b6a8ebf3a45d509689c1d4852c51d9ba54e5b294fab12a989c502
Forward PE Ratio (16.52) = Dated Quote Price ($31.05) / Consensus Forward EPS ($1.88)
FORWARD PE RATIO
16.52
SECTOR MEDIAN · HEALTHCARE
19.83
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
-16.69%
vs the sector median at left
Option Care Health, Inc.
Market Cap
$4.65B
Forward PE Ratio
16.52
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Option Care Health, Inc. (OPCH) | $4.65B | 16.52 |
| BillionToOne, Inc. (BLLN)vs › | $4.67B | 127.95 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.68B | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 75.23 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.70B | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.78B | N/A |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.81B | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.46B | 8.47 |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.41B | N/A |
| Erasca, Inc. (ERAS)vs › | $4.94B | N/A |
Trailing P/E
23.4
reported TTM EPS
Forward P/E
16.5
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.88 implies +41.4% EPS growth vs the reported trailing $1.33.
At the dated quote price of $31.05, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.88 | $1.86 – $1.93 | 8 | 16.5x |
| 2027-12-31 | $2.08 | $2.04 – $2.12 | 8 | 14.9x |
| 2028-12-31 | $2.33 | $2.11 – $2.62 | 6 | 13.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
